Details of the Drug

General Information of Drug (ID: DM7N4H9)

Drug Name

TAK-925

Synonyms

Danavorexton; TAK-925; 2114324-48-8; Danavorexton [INN]; 1QMD83K4YN; (2R,3S)-Methyl 3-(methylsulfonamido)-2-(((cis-4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate; 1-Piperidinecarboxylic acid, 3-((methylsulfonyl)amino)-2-(((cis-4-phenylcyclohexyl)oxy)methyl)-, methyl ester, (2R,3S)-; Methyl (2R,3S)-3-((methylsulfonyl)amino)-2-(((cis-4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate; methyl (2R,3S)-3-[(methanesulfonyl)amino]-2-({[(1s,4S)-4-phenylcyclohexyl]oxy}methyl)piperidine-1-carboxylate; A6F; UNII-1QMD83K4YN; TAK925; CHEMBL4650341; SCHEMBL19219900; GTPL11448; US10287305, Example 5; BDBM386067; BDBM386216; DTXSID401336757; GLXC-25309; EX-A6332; Example 5 [US10287305]; US10287305, Example 191; AKOS040757301; MS-27472; HY-133898; CS-0135024; EN300-2010728; methyl (2R,3S)-3- ((methylsulfonyl)amino)-2-(((cis-4- phenylcyclohexyl)oxy)methyl)- piperidine-1-carboxylate; methyl (2R,3S)-3-(methanesulfonamido)-2-[(4-phenylcyclohexyl)oxymethyl]piperidine-1-carboxylate; methyl (2R,3S)-3-methanesulfonamido-2-({[(1s,4s)-4-phenylcyclohexyl]oxy}methyl)piperidine-1-carboxylate; methyl-d3 (2R,3S)-3- ((methylsulfonyl)amino)-2-(((cis-4- phenylcyclohexyl)oxy)methyl)- piperidine-1-carboxylate

Indication

Disease Entry	ICD 11	Status	REF
Narcolepsy	7A20	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecule

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C21H32N2O5S
Canonical SMILES: COC(=O)N1CCCC(C1COC2CCC(CC2)C3=CC=CC=C3)NS(=O)(=O)C
InChI: InChI=1S/C21H32N2O5S/c1-27-21(24)23-14-6-9-19(22-29(2,25)26)20(23)15-28-18-12-10-17(11-13-18)16-7-4-3-5-8-16/h3-5,7-8,17-20,22H,6,9-15H2,1-2H3/t17?,18?,19-,20-/m0/s1
InChIKey: UXZAJSZFFARTEI-GUMHCPJTSA-N

Cross-matching ID

PubChem CID: 130310079
TTD ID: DZ2PC5

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Orexin receptor type 2 (HCRTR2)	TT9N02I	OX2R_HUMAN	Agonist	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT03748979) A 3-Part, Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-925 in Healthy Volunteers and Patients With Narcolepsy. U.S.National Institutes of Health.
2	Molecular mechanism of the wake-promoting agent TAK-925. Nat Commun. 2022 May 25;13(1):2902.